To describe the clinical and therapeutic management of rheumatoid arthritis (RA) patients with biological disease-modifying antirheumatic drugs (bDMARDs), alone or in combination with conventional synthetic DMARDs (csDMARDs), as well as analysing changes over time in bDMARD use. An observational, retrospective, multicentre study was conducted in the rheumatology departments of 10 public Spanish hospitals. Patients with RA treated with bDMARDs at baseline who had medical records available in the data collection period 2013-2016 were included. All visits to rheumatology departments recording any type of bDMARD modification (dose, etc.) were collected. Clinical characteristics, concomitant treatment, resource use, work productivity and quality of life (QoL) were recorded. 128 patients were included: 81 received first-line bDMARD treatment, 28 second-line bDMARD treatment and 19 received third or later lines. Mean study follow-up was 4.1 years. Assessment of DAS28 was available in 54.6% of visits. At baseline, 48.7% of patients had moderate-high disease activity. At final observation, 69.5% of patients continued with the first bDMARD. Tumour necrosis factor blockers were administered to 85.2% of patients in first line, 45.7% in second line and 18.1% in third or later lines. At final observation, 80.2% of patients still felt pain/discomfort. As expected, those with higher disease activity had higher loss of work productivity and lower QoL, as assessed by DAS28, than patients with lower disease activity. Drugs represented 82.6% of the total cost. In this Spanish cohort of 128 patients, most patients remained on the first prescribed bDMARD, despite remaining signs and symptoms.

中文翻译：

---

使用可改善生物疾病的抗风湿药治疗类风湿关节炎的临床和治疗方法：RADAR研究。

描述单独或与常规合成DMARD（csDMARD）结合使用可改善生物疾病的抗风湿药（bDMARD）的类风湿关节炎（RA）患者的临床和治疗管理，以及分析bDMARD使用随时间的变化。在西班牙的10家公立医院的风湿病科进行了一项观察性，回顾性，多中心研究。纳入在基线期接受bDMARD治疗的RA患者，这些患者在2013-2016年数据收集期间可提供医疗记录。收集所有风湿病科访视记录，记录任何类型的bDMARD修饰（剂量等）。记录临床特征，伴随治疗，资源利用，工作效率和生活质量（QoL）。其中包括128位患者：81位接受了一线bDMARD治疗，28例二线bDMARD治疗和19例接受第三线或以后的治疗。平均研究随访时间为4.1年。对DAS28的评估在54.6％的访问中可用。基线时，有48.7％的患者患有中度高疾病活动。最终观察到，有69.5％的患者继续进行首次bDMARD治疗。一线患者中有85.2％的患者使用了肿瘤坏死因子阻滞剂，二线患者中的比例为45.7％，三线或以后的患者中为18.1％。最终观察时，仍有80.2％的患者感到疼痛/不适。正如预期的那样，根据DAS28的评估，疾病活动度较高的患者比疾病活动度较低的患者具有更高的工作效率损失和更低的QoL。药品占总成本的82.6％。在这个西班牙的128位患者队列中，尽管仍然有体征和症状，但大多数患者仍接受了首次开具bDMARD的处方。